tirzepatide 0.25 mg In adults with obesity but not diabetes, leads to significantly greater weight loss than semaglutide over 72 weeks, and nearly double the patients on tirzepatide meet the 25% weight-loss target. http://ms.spr.ly/6183SkuIL Tirzepatide Dosing for Weight Loss

(source: biospace.com) Semaglutide Market Segmentation By Product Outlook (Revenue USD Billion, 20212034) Ozempic Wegovy Rybelsus Others By Application Outlook (Revenue USD Billion, 20212034) Type 2 Diabetes Mellitus Obesity Others By Route of Administration Outlook (Revenue USD Billion, 20212034) Parenteral Oral By Distribution Channel Outlook (Revenue USD Billion, 20212034) Hospital Pharmacies Retail Pharmacies Online Pharmacies By Regional Outlook (Revenue USD Billion, 20212034) North America U.S

In the survodutide arm (a GLP-1 and glucagon receptor dual agonist), liver mass dropped 55% while muscle loss in the casted leg was comparable across semaglutide, survodutide, and pair-fed controls

Hathaway JT, et al

In the OASIS 4 trial, adults taking the 25mg tablet lost an average of 13.6% of their body weight over 64 weeks, compared with 2.2% on placebo